Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097317 - EXPLOITING ESTROGEN RECEPTOR BETA AND TP53 INTERACTION AS A NEW THERAPEUTIC STRATEGY FOR CANCER

Publication Number WO/2020/097317
Publication Date 14.05.2020
International Application No. PCT/US2019/060248
International Filing Date 07.11.2019
IPC
A61K 31/138 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Applicants
  • HEALTH RESEARCH, INC. [US]/[US]
Inventors
  • DAS, Gokul M.
Agents
  • SMALLEY, Laura W.
Priority Data
62/756,69907.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) EXPLOITING ESTROGEN RECEPTOR BETA AND TP53 INTERACTION AS A NEW THERAPEUTIC STRATEGY FOR CANCER
(FR) EXPLOITATION D'UNE INTERACTION ENTRE LE RÉCEPTEUR BÊTA DES ŒSTROGÈNES ET TP53 EN TANT QUE NOUVELLE STRATÉGIE THÉRAPEUTIQUE POUR LE CANCER
Abstract
(EN)
To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.
(FR)
Selon l'invention, pour induire la mort des cellules cancéreuses, des cellules cancéreuses qui expriment le récepteur β des œstrogènes (ERβ) et la protéine tumorale 53 (TP53) mutante sont sélectionnées. Un agent qui augmente l'expression de la protéine ERβ est administré aux cellules pour induire la mort cellulaire. Pour traiter un sujet atteint d'un cancer qui est caractérisé par des cellules cancéreuses exprimant ERβ et TP53 mutante, un agent qui augmente l'expression de la protéine ERβ est administré pour induire la mort cellulaire dans les cellules cancéreuses. Pour augmenter les taux d'expression du récepteur β des œstrogènes (ERβ) chez un sujet ayant des taux d'expression d'ERβ faibles, le tamoxifène est administré pour augmenter les taux de protéine ERβ chez le sujet. Pour traiter un sujet ayant des cellules cancéreuses exprimant le récepteur β des œstrogènes (ERβ) et la protéine tumorale 53 (TP53) de type sauvage, un agent qui inhibe l'interaction de la liaison ERβ et TP53 est administré pour induire la mort cellulaire dans les cellules cancéreuses du sujet.
Latest bibliographic data on file with the International Bureau